Practical Steps for Diagnosing Early-Onset Sepsis in Newborns

Recent Trends

Clinical approaches to early-onset neonatal sepsis are shifting from universal, prolonged antibiotic courses toward risk-stratified management. Many hospitals now incorporate validated prediction tools that combine maternal history, infant clinical status, and serial laboratory results. These tools help reduce unnecessary antibiotic exposure without missing true infections.

Point-of-care biomarkers, such as serial C-reactive protein and procalcitonin measurements, are being used alongside complete blood counts to guide decisions. Some centers are also piloting multiplex polymerase chain reaction (PCR) panels to identify pathogens more quickly than conventional culture, although standard blood culture remains the gold standard.

• Increasing adoption of sepsis risk calculators (e.g., Kaiser Permanente neonatal sepsis calculator) that adjust management based on maternal risk factors, clinical exam, and lab values.
• Growing evidence that a “watchful waiting” period with serial clinical assessments can safely rule out infection in asymptomatic infants born to mothers with chorioamnionitis.
• Limited but emerging use of molecular diagnostic panels for rapid pathogen detection in symptomatic neonates.

Background

Early-onset sepsis (EOS) typically presents within the first 72 hours of life, most often from vertical transmission of group B Streptococcus or Escherichia coli. Traditional diagnostic protocols relied on a low threshold for starting empiric antibiotics due to the high mortality risk of untreated infection. However, this approach led to large numbers of healthy infants receiving broad-spectrum antibiotics, which disrupts the developing microbiome and may contribute to antimicrobial resistance.

Historically, diagnosis was based on a combination of maternal fever, prolonged rupture of membranes, and the infant’s clinical signs—respiratory distress, temperature instability, or poor feeding. Because these signs are non-specific, clinicians frequently pursued full septic workups including lumbar puncture. Over time, data showed that many low-risk infants could be managed with less invasive testing.

User Concerns

Parents and clinicians face a tension between missing a life-threatening infection and subjecting a well-appearing newborn to the risks of antibiotics, separation from the mother, and painful procedures. Common worries include:

• Will delaying antibiotics allow sepsis to progress if the decision tool is wrong?
• How reliable are current biomarkers and clinical calculators in the first hours of life?
• What are the consequences of unnecessary antibiotics on breastfeeding and the infant’s gut health?
• How to balance the desire for immediate certainty with the reality that cultures take 24‑48 hours to finalize.

Many families also express confusion when care varies between hospitals—some centers routinely start antibiotics for any risk factor, while others use stringent criteria before intervening.

Likely Impact

Wider adoption of structured diagnostic protocols will likely reduce antibiotic use among asymptomatic newborns while maintaining safety. Hospitals that implement these protocols report fewer infants transferred to intensive care units solely for observation, shorter lengths of stay, and lower costs. The shift also supports antimicrobial stewardship goals by limiting exposure to broad-spectrum drugs.

However, the impact depends heavily on local context. Facilities with limited laboratory turnaround times or insufficient nursing staff to perform serial exams may struggle to adopt watchful waiting. In settings with high maternal GBS colonization rates or limited prenatal screening, calculators may need local recalibration. Over time, improved rapid testing (e.g., PCR for GBS and E. coli directly from blood) could make the diagnostic process even faster and more accurate.

“The goal is not to eliminate antibiotics entirely, but to target them to infants who truly need them,” summarizes a recent clinical guideline. “Risk stratification allows us to treat sepsis without treating every infant as if they have sepsis.”

What to Watch Next

Several developments are on the horizon that could further refine EOS diagnosis:

• Integration of electronic health record (EHR) decision support: Automated prompts that combine maternal and infant data in real time, potentially flagging high-risk cases while reducing reliance on manual calculator entry.
• Validation of new biomarkers: Research into cytokines (e.g., IL-6, IL-8) and cell-surface markers that might detect infection before clinical signs emerge.
• Standardization of clinical criteria: Ongoing efforts by pediatric infectious disease societies to unify definitions of “low-risk” and “high-risk” for EOS, which could reduce inter-hospital variability.
• Expanded molecular testing: If rapid multiplex PCR panels become reliable for blood and cerebrospinal fluid in neonates, they could offer a same-day alternative to cultures.

Clinicians should monitor updated guidance from their local health authorities and consider periodic audits of their own outcomes to ensure that protocol changes do not inadvertently miss infections. For families, understanding that early discharge with a plan for home follow-up may be a reasonable alternative to prolonged observation remains an important part of shared decision-making.